Company intelligence / Profile preview

Oxyrane

Manchester, United Kingdomoxyrane.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Oxyrane is developing enhanced enzyme replacement therapies with superior pharmacodynamics. Their lead program for Gaucher Disease has demonstrated superior pharmacodynamic effects in disease animal models. They are also advancing a treatment for Pompe disease through preclinical stages.

Therapeutic areas: Rare Diseases
Modalities: Enzyme Replacement Therapies (ERTs)
Industry: Biotech

Drug pipeline

1 asset

OXY-GAA

Phase 1/2

Indications: Pompe disease

Partnerships

Bioasis Technologies Inc.

Beyond the preview

Go deeper on Oxyrane.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxyrane.

Explore the full profile